Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers

Anand Sharma; Deshveer Babra; Priya Joshi; Marcia Hall; Andrew Gogbashian; Nikhil Vasdev; Magdalene Joseph; Amir Yazdan; Edward Kanfer

doi:10.21873/invivo.12215

Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers

Anand Sharma, Deshveer Babra, Priya Joshi, Marcia Hall, Andrew Gogbashian, Nikhil Vasdev, Magdalene Joseph, Amir Yazdan, Edward Kanfer

Research output: Contribution to journal › Article › peer-review

16 Downloads (Pure)

Abstract

Background/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.
Patients and Methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes.
Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients had peripheral neurotoxicity (≥Grade 2) (50%), 4 patients developed renal failure, 5 had ototoxicity (≥Grade 2) and 1 patient developed acute myeloid leukaemia. Median survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance.
Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.

Original language	English
Pages (from-to)	3675-3679
Number of pages	5
Journal	In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research
Volume	34
Issue number	6
DOIs	https://doi.org/10.21873/invivo.12215
Publication status	Published - Nov 2020

Keywords

High dose chemotherapy
Relapsed germ cell cancer
Stem cell transplant
Survival

Access to Document

10.21873/invivo.12215

3675_full
© 2020 The Author(s). The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited.
Final published version, 107 KBLicence: Unspecified

Cite this

Sharma, A., Babra, D., Joshi, P., Hall, M., Gogbashian, A., Vasdev, N., Joseph, M., Yazdan, A., & Kanfer, E. (2020). Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers. In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research, 34(6), 3675-3679. https://doi.org/10.21873/invivo.12215

@article{92f25e89cad14630a62d161acafbd830,

title = "Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers",

abstract = "Background/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.Patients and Methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients had peripheral neurotoxicity (≥Grade 2) (50%), 4 patients developed renal failure, 5 had ototoxicity (≥Grade 2) and 1 patient developed acute myeloid leukaemia. Median survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.",

keywords = "High dose chemotherapy, Relapsed germ cell cancer, Stem cell transplant, Survival",

author = "Anand Sharma and Deshveer Babra and Priya Joshi and Marcia Hall and Andrew Gogbashian and Nikhil Vasdev and Magdalene Joseph and Amir Yazdan and Edward Kanfer",

note = "{\textcopyright} 2020 The Author(s). The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited.",

year = "2020",

month = nov,

doi = "10.21873/invivo.12215",

language = "English",

volume = "34",

pages = "3675--3679",

journal = "In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research",

issn = "1791-7549",

publisher = "International Institute of Anticancer Research",

number = "6",

}

Sharma, A, Babra, D, Joshi, P, Hall, M, Gogbashian, A, Vasdev, N, Joseph, M, Yazdan, A & Kanfer, E 2020, 'Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers', In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research, vol. 34, no. 6, pp. 3675-3679. https://doi.org/10.21873/invivo.12215

Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers. / Sharma, Anand; Babra, Deshveer; Joshi, Priya et al.
In: In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research, Vol. 34, No. 6, 11.2020, p. 3675-3679.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers

AU - Sharma, Anand

AU - Babra, Deshveer

AU - Joshi, Priya

AU - Hall, Marcia

AU - Gogbashian, Andrew

AU - Vasdev, Nikhil

AU - Joseph, Magdalene

AU - Yazdan, Amir

AU - Kanfer, Edward

N1 - © 2020 The Author(s). The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited.

PY - 2020/11

Y1 - 2020/11

N2 - Background/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.Patients and Methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients had peripheral neurotoxicity (≥Grade 2) (50%), 4 patients developed renal failure, 5 had ototoxicity (≥Grade 2) and 1 patient developed acute myeloid leukaemia. Median survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.

AB - Background/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs.Patients and Methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients had peripheral neurotoxicity (≥Grade 2) (50%), 4 patients developed renal failure, 5 had ototoxicity (≥Grade 2) and 1 patient developed acute myeloid leukaemia. Median survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.

KW - High dose chemotherapy

KW - Relapsed germ cell cancer

KW - Stem cell transplant

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85095602214&partnerID=8YFLogxK

U2 - 10.21873/invivo.12215

DO - 10.21873/invivo.12215

M3 - Article

SN - 1791-7549

VL - 34

SP - 3675

EP - 3679

JO - In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research

JF - In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research

IS - 6

ER -

Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this